Gene therapy is emerging as a promising treatment for neurological diseases, particularly for Parkinson's disease.

Michael Kaplitt, MD, PhD, from Weill Cornell Medicine emphasizes gene therapy's potential in addressing the slow progression characteristic of neurodegenerative disorders.

The therapy involves delivering engineered genes for more efficient expression in the Central Nervous System (CNS), possibly altering dopamine production and neuronal phenotype for lasting therapeutic effects.

Compared to traditional drug discovery, gene therapy could streamline the treatment development process for neurological diseases.

Kaplitt notes the importance of identifying suitable candidates for gene therapy, suggesting that patient selection is key in these neurological applications.

Gene therapy is positioned as a significant advancement with the potential to change the treatment landscape for Parkinson's and other neurodegenerative diseases, promising better outcomes in the future.